
Lifeward Ltd.
99
Recent developments include leadership changes, clinical study results, and financial performance updates.
- Lifeward appointed Ronen Tsimerman as Chief Financial Officer effective November 1, 2026 [N7].
- A study showed the ReWalk exoskeleton improves daily activities, satisfaction, and pain for users [N6].
- Josh Hexter was named Interim CEO and Rami Aviram as CFO in September 2026 [N7].
- Lifeward reported Q2 2026 revenue up 16%, citing commercial momentum supporting the second half of the year [N8].
- The company reported a Q2 2026 loss and missed revenue estimates [N8].
Lifeward Ltd. is a medical device company specializing in powered exoskeleton systems designed to assist individuals with mobility impairments due to spinal cord injuries or stroke. Its flagship product, the ReWalk Personal Exoskeleton, has received FDA de novo classification and multiple 510(k) clearances, including for stair and curb functionality and next-generation models. The company also markets the ReStore device for rehabilitation institutions. Lifeward maintains compliance with FDA Quality Management System Regulation and ISO standards, and its products hold CE marks or MDR certification for the European market. The company is subject to extensive regulatory oversight including healthcare fraud and data privacy laws. Recent leadership transitions include an interim CEO and new CFO appointments. Financially, Lifeward reported $5.43 million in revenue and a net loss of $5.05 million for Q3 2026, with liquidity ratios indicating moderate short-term financial stability. The company faces risks related to customer concentration, regulatory classification challenges in the EU, political uncertainties, and the integration of AI-enabled technologies.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Lifeward Ltd. develops and markets powered exoskeleton medical devices such as the ReWalk Personal Exoskeleton and ReStore device, with FDA and EU regulatory clearances. The company reported Q3 2026 revenue of $5.43 million and a net loss of $5.05 million, with a current ratio of 2.0 as of September 30, 2026. Recent leadership changes include appointment of an interim CEO and new CFO. Lifeward faces regulatory, operational, and market risks including customer concentration and evolving AI technology regulations.
Lifeward's regulatory approvals for advanced exoskeleton models and positive clinical study results demonstrate its capability to develop innovative rehabilitation technologies. The company's commercial momentum, as indicated by revenue growth and new leadership appointments, supports operational execution. Its compliance with international quality standards and expanding product portfolio position it to address growing demand for mobility assistance devices. Strategic partnerships and controlling shareholder support may facilitate resource access and market expansion.
Lifeward faces risks from recent leadership changes that could disrupt strategic execution and operational continuity. Customer concentration in trade receivables poses financial risk if key customers reduce purchases or delay payments. Regulatory challenges, including potential reclassification of products in the EU and evolving AI technology regulations, may increase compliance costs or delay market access. Political uncertainties in the US and Israel could affect reimbursement policies and government support. The company reported net losses and negative earnings per share, indicating ongoing profitability challenges.
Lifeward's moat is anchored in its regulatory clearances and certifications for powered exoskeleton devices, including FDA de novo classification and EU MDR certification, which create barriers to entry for competitors. Its proprietary technology for mobility assistance and rehabilitation, combined with compliance to stringent quality management systems and clinical validation, supports its competitive positioning. The company's relationships with contract manufacturers and regulatory bodies, as well as its ongoing product development and clinical studies, further reinforce its market presence. However, the medical device industry is subject to evolving regulations and competitive pressures that require continuous innovation and compliance.
• Leadership Transition Risk: Recent significant changes in senior management and Board of Directors may disrupt business operations, cause loss of institutional knowledge, and divert management attention, potentially impairing execution of strategy and financial reporting [S2].
• Customer Concentration Risk: A significant portion of trade receivables is attributable to a single customer, creating risk of adverse impact on cash flows and results if this customer reduces purchases or delays payments [S2].
• Regulatory Compliance Risk: Lifeward is subject to extensive FDA and EU regulations including device classification, quality management systems, and data privacy laws. Failure to comply could result in enforcement actions, fines, product recalls, or loss of market access [S1][S2].
• AI Technology Risk: Development and incorporation of AI-enabled technologies involve evolving regulatory requirements and operational risks including product performance, safety, and cybersecurity [S2].
• Political and Legislative Risk: Changes in US Congress composition and political uncertainty in Israel may affect healthcare reimbursement, regulatory priorities, and government support impacting Lifeward's operations [S2].
• Controlling Shareholder Influence: Oramed's significant ownership and influence may lead to conflicts of interest or decisions that do not align with other shareholders' interests [S2].
Business trends: Lifeward is advancing powered exoskeleton technologies with regulatory clearances and clinical validation, while expanding commercial momentum.
Execution milestones: Integration of new leadership, maintaining regulatory compliance including FDA and EU certifications, and managing customer relationships are key focus areas.
Key risks: Leadership transitions, regulatory compliance challenges, customer concentration, and political uncertainties pose significant operational and financial risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Lifeward Ltd. develops and markets powered exoskeleton medical devices, including the ReWalk Personal Exoskeleton and ReStore device, intended to assist individuals with spinal cord injuries and stroke-related hemiplegia or hemiparesis respectively under supervision of trained personnel [S1].
- The ReWalk Personal Exoskeleton received FDA de novo classification as a Class II powered exoskeleton device in June 2014, with subsequent 510(k) clearances in March 2023 for stair and curb functionality and in March 2025 for the ReWalk 7 Personal Exoskeleton model [S1].
- The ReStore device received FDA 510(k) clearance in June 2019 and is intended for rehabilitation institutions under therapist supervision [S1].
- In the European Union, Lifeward's ReWalk 7 Personal Exoskeleton received MDR certification in September 2025, while prior ReWalk models remain CE marked under transitional provisions; the ReStore device sales ceased in the EU in May 2024 due to regulatory changes [S1].
- Lifeward and its contract manufacturers comply with FDA Quality Management System Regulation (QMSR) effective February 2026 and ISO 13485:2016 standards, with periodic inspections by regulatory agencies [S1].
- The company is subject to extensive regulatory requirements including FDA general and special controls, EU MDR, data privacy laws such as HIPAA and GDPR, anti-bribery laws including the FCPA, and other healthcare fraud and abuse laws [S1].
- Recent leadership changes include appointment of Josh Hexter as Interim CEO effective September 1, 2026, departure of former CFO effective September 30, 2026, and appointment of Ronen Tsimerman as CFO effective November 1, 2026 [N7][S2].
- Lifeward reported Q3 2026 financial results with revenue of $5.43 million and net loss of $5.05 million for the quarter ended September 30, 2026; basic and diluted EPS were -$1.32 [S2].
- As of September 30, 2026, Lifeward had cash and equivalents of $4.55 million, current assets of $21.7 million, current liabilities of $10.85 million, resulting in a current ratio of 2.0 and cash ratio of 0.42 [S2].
- A significant portion of Lifeward's trade receivables as of September 30, 2026, was attributable to a single customer, posing concentration risk [S2].
- Lifeward is developing AI-enabled technologies for rehabilitation devices, which may involve evolving regulatory and operational risks [S2].
- The company faces regulatory scrutiny in the EU regarding classification of certain products (Neo and Neo+ Anti-Gravity Treadmill) which may require reclassification and conformity assessments [S2].
- Political and legislative changes in the US and Israel may affect Lifeward's regulatory environment, reimbursement, and government support [S2].
- Oramed is Lifeward's controlling shareholder with approximately 44.2% ownership, influencing company operations and governance [S2].
- Recent news highlights include a study showing the ReWalk exoskeleton improves daily activities, satisfaction, and pain [N6], and commercial momentum with Q2 revenue up 16% reported in August 2026 [N8].
Generated 2026-11-13
- S1 | 2026-03-18 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/biostem-technologies-inc-bsem-reports-q3-loss-beats-revenue-estimates
- N2 | 2026-11-09 | www.nasdaq.com | Surgery Partners (SGRY) Beats Q3 Earnings Estimates | https://www.nasdaq.com/articles/surgery-partners-sgry-beats-q3-earnings-estimates
- N3 | 2026-11-05 | www.nasdaq.com | Viatris (VTRS) Q3 Earnings Beat Estimates | https://www.nasdaq.com/articles/viatris-vtrs-q3-earnings-beat-estimates
- N4 | 2026-11-04 | www.nasdaq.com | Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/progyny-pgny-tops-q3-earnings-and-revenue-estimates
- N5 | 2026-11-03 | www.nasdaq.com | PACS Group, Inc. (PACS) Q3 Earnings and Revenues Beat Estimates | https://www.nasdaq.com/articles/pacs-group-inc-pacs-q3-earnings-and-revenues-beat-estimates
- N6 | 2026-09-15 | www.nasdaq.com | Lifeward Study Shows ReWalk Exoskeleton Improves Daily Activities, Satisfaction And Pain | https://www.nasdaq.com/articles/lifeward-study-shows-rewalk-exoskeleton-improves-daily-activities-satisfaction-and-pain
- N7 | 2026-09-01 | www.nasdaq.com | Lifeward Names Josh Hexter Interim CEO, Rami Aviram As CFO | https://www.nasdaq.com/articles/lifeward-names-josh-hexter-interim-ceo-rami-aviram-cfo
- N8 | 2026-08-14 | www.nasdaq.com | Lifeward Q2 Revenue Up 16%; Commercial Momentum Supports Second-Half Outlook | https://www.nasdaq.com/articles/lifeward-q2-revenue-16-commercial-momentum-supports-second-half-outlook
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


